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	 1‐((5,3‐Diaryl)‐4,5‐dihydro‐1H‐pyrazol‐1‐yl)propan‐1‐one,	 6‐10,	 have	 been	 synthesized	 by
the	 reaction	 of	 chalcone	 derivatives,	 1‐5,	 with	 hydrazine	 hydrate	 in	 hot	 propanoic	 acid
solution.	All	these	compounds	were	characterized	by	different	spectroscopic	techniques	(FT‐
IR,	1H	and	13C	NMR)	and	elemental	analyses.	All	the	synthesized	products	were	evaluated	for
antimicrobial	 activity.	 All	 the	 compounds	 exhibited	 significant	 to	 moderate	 antimicrobial
activity.	
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1.	Introduction	
	
Heterocyclic	 compounds	 have	 so	 far	 been	 synthesized	
mainly	 due	 to	 the	 wide	 range	 of	 biological	 activities.	 Much	
attention	 has	 been	 paid	 to	 the	 synthesis	 of	 heterocyclic	
compounds	 bearing	 nitrogen	 containing	 ring	 system,	 like	
pyrazoles	mainly	due	 to	 their	higher	pharmacological	 activity.	
Over	 the	 years,	 the	 chemistry	 of	 1H‐pyrazoles	 has	 received	
considerable	 attention	 [1,2].	 It	 is	 worthy	 of	 note	 that	
substances	 containing	 a	 1H‐pyrazole	 moiety	 have	 been	
described	as	having	potential	 therapeutic	utility,	 such	 as	 anti‐
inflammatory	 [3‐5],	 antidepressant	 [6,7],	 antipyretic	 [8],	
antibacterial	[9‐14],	antifungal	[12,15]	and	antitumoral	[16].	Of	
particular	 interest	 is	 the	 use	 of	 1H‐pyrazoles	 as	 synthetic	
intermediates	for	preparing	cyclopropane	[17‐19]	and	pyrazole	
derivatives	[1,20‐26].	1H‐Pyrazoles	have	usually	been	prepared	
by	starting	from	aldehydes	or	ketones,	which	have	either	actual	
or	 potential	 α,β‐unsaturation	 [1,27‐41].	 1,3‐Dipolar	 cyclo‐
additions	 between	 diazoalcanes	 and	 different	 types	 of	
molecules	 containing	 activated	 double	 bonds	 are	 also	
exploitable	reactions	[1,16,17,42,43].		
In	 our	 case,	 substituted	 chalcones,	1‐5,	were	 prepared	 by	
the	 reaction	 of	 benzaldehyde	 derivatives	 with	 acetophenone	
derivatives	 in	 the	 presence	 of	 aqueous	 solution	 of	 sodium	
hydroxide	 and	 ethanol	 by	 the	 Claisen‐Schmidt	 condensation	
method	 to	 afford	 corresponding	 1‐((5,3‐diaryl)‐4,5‐dihydro‐
1H‐pyrazol‐1‐yl)propan‐1‐one,	 6‐10,	 by	 their	 1,3‐dipolar	
cycloaddition	 to	 hydrazine	 hydrate	 in	 hot	 propanoic	 acid	
solution.	
	
2.	Experimental	
	
2.1.	Instrumentation	
Melting	 points	 were	 determined	 with	 (Bransted/‐
Electrothermal)	 apparatus	 and	 are	 uncorrected.	 IR	 spectra	
were	 recorded	 for	 KBr	 pellets	 on	 a	 Perkin‐Elmer	 FT‐IR‐01	
spectrophotometer.	1H	and	13C	NMR	spectra	are	recorded	on	a	
Bruker	 spectrometer	 respectively	 at	 400	 and	 at	 100	 MHz	 in	
CDCl3	 (internal	 standard	 TMS,	 δ	 =	 0.0	 ppm)	 at	 room	
temperature.	TLC	were	performed	on	Kieslgel	60	F254	 (Merck)	
layer	 using	 toluene:	 ethyl	 acetate	 (3:2,	 v:v)	 as	 eluents.	
Elemental	 analyses	 were	 performed	 on	 Perkin‐Elmer	 240B	
micro	analyser,	and	the	analytical	results	were	within	±0.4%	of	
the	theoretical	values.	
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	chalcones	(1‐5)		
	
A	 mixture	 of	 substituted	 acetophenones	 (0.01	 mole)	 and	
substituted	benzaldehydes	 (0.01	mole)	was	 stirred	 in	 ethanol	
(50	mL)	and	then	a	solution	of	15	mL	sodium	hydroxide	(0.04	
mole)	was	added.	The	mixture	was	kept	for	four	hours	at	room	
temperature	 and	 then	 it	 was	 poured	 into	 crushed	 ice	 and	
acidified	with	diluted	HCl.	The	chalcones	derivative	precipitates	
out	 as	 solid.	 Then	 it	 was	 filtered	 and	 crystallized	 from	 ethyl	
acetate	(Scheme	1)	[44].	
	
2.2.2.	Synthesis	of	1‐((5,3‐diaryl)‐4,5‐dihydro‐1H‐pyrazol‐1‐
yl)propan‐1‐one,	6‐10	 	
	
A	 mixture	 of	 chalcone	 derivatives	 (1‐5,	 10	 mmoles),	
hydrazine	 hydrate	 (50	 mmoles)	 and	 propanoic	 acid	 (40	 mL)	
was	 refluxed	 for	 12	 hours	 then	 poured	 into	 crushed	 ice.	 The	
precipate	was	separated	by	 filtration,	washed	 free	of	acid	and	
crystallized	 from	ethanol	to	afford	1‐((5,3‐diaryl)‐4,5‐dihydro‐
1H‐pyrazol‐1‐yl)propan‐1‐one,	6‐10	(Scheme	1).	
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Scheme	1	
	
	
1‐(5‐(4‐Isopropylphenyl)‐3‐(4‐phenyl)‐4,5‐dihydro‐1H‐
pyrazol‐1‐yl)propan‐1‐one	 (6):	 Color:	 Pal	 crystal.	 Yield:	 70%.	
M.p.:	140‐141	°C.	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.12	(3H,	t,	
CH3),	1.23	(6H,	d,	J	=	6.9	Hz,	CH(CH3)2),	2.54	(2H,	q,	CH2),	2.90	
(1H,	 sept,	 J	=	6.9	Hz,	 CH(CH3)2),	 3.32	 (1H,	 dd,	 J=	4.6,	 17.7	Hz,	
HA),	 3.82	 (1H,	 dd,	 J	=	11.8,	 17.7	Hz,	HB),	 5.52	 (1H,	dd,	 J	=	4.6,	
17.7	Hz,	HX),	7.78‐7.69	 (2H	m,	H	Ar),	7.48‐7.38	 (3H,	m,	H	Ar),	
7.22‐7.14	 (4H,	 m,	 H	 Ar).	 13C	 NMR	 (100	MHz,	 CDCl3,	 δ,	 ppm):	
15.12,	23.90,	23.92,	33.77,	40.52,	42.60,	58.80,	125.62,	126.69,	
127.08,	 128.81,	 130.62,	 130.97,	 137.94,	 148.59,	 160.10.	 Anal.	
calcd.	for	C21H24N2O:	C,	78.71;	H,	7.55;	N,	8.74.	Found:	C,	78.69;	
H,	7.52;	N,	8.70%.	
1‐(5‐(4‐Bromophenyl)‐3‐(4‐hydroxyphenyl)‐4,5‐dihydro‐1H‐
pyrazol‐1‐yl)propan‐1‐one	 (7):	 Color:	 Pal	 crystal.	 Yield:	 80%.	
M.p.:	148‐149	°C.	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.16	(3H,	t,	
CH3),	2.52	(2H,	q,	CH2),	3.28	(1H,	dd,	J	=	18.4,	4.8	Hz,	HA),	3.85	
(1H,	dd,	J	=	18.4,	11.9	Hz,	HB),	5.54	(1H,	dd,	J	=	11.9,	4.8,	1.0	Hz,	
HX),	7.44‐7.41	(2H,	m,	H	Ar),	7.29‐7.27	(2	H,	m,	H	Ar),	7.18‐7.14	
(4H,	m,	H	Ar),	10.08	(1H,	s,	OH).	 13C	NMR	(100	MHz,	CDCl3,	δ,	
ppm):	 15.14,	 40.55,	 41.98,	 58.89;	 125.71,	 126.75,	 127.25,	
128.91,	 131.42,	 131.72,	 139.14,	 148.09,	 155.25,	 160.10.	 Anal.	
calcd.	 for	 C18H17BrN2O2:	 C,	 57.92;	 H,	 4.59;	 N,	 7.50.	 Found:	 C,	
57.47;	H,	4.52;	N,	7.46%.	
1‐(5‐(4‐Bromophenyl)‐3‐(4‐chlorophenyl)‐4,5‐dihydro‐1H‐
pyrazol‐1‐yl)propan‐1‐one	 (8):	 Color:	 Pal	 yellow	 crystal.	 Yield:	
87%.	M.p.:	144‐145	°C.	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.14	
(3H,	t,	CH3),	2.53	(2H,	q,	CH2),	3.27	(1H,	dd,	J	=	18.3,	4.8	Hz,	HA),	
3.82	(1H,	dd,	J	=	18.3,	11.8	Hz,	HB),	5.53	(1H,	dd,	J	=	11.8,	4.8,	1.0	
Hz,	HX),	 7.45‐7.30	 (4H,	m,	H	Ar),	 7.25‐7.20	 (4H,	m,	H	Ar).	 13C	
NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 15.17,	 40.57,	 42.40,	 57.70,	
125.60,	126.59,	127.02,	128.80,	130.59,	130.95,	137.86,	148.48,	
155.83,	160.15.	Anal.	calcd.	for	C18H16BrClN2O:	C,	55.19;	H,	4.11;	
N,	7.15,	Found:	C,	55.12;	H,	4.07;	N,	7.11%.	
1‐(5‐(4‐Isopropylphenyl)‐3‐(4‐chlorophenyl)‐4,5‐dihydro‐1H‐
pyrazol‐1‐yl)propan‐1‐one	 (9):	 Colar:	 Pal	 crystal.	 Yield:	 76%.	
M.p.:	142‐143	°C.	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.18	(3H,	t,	
CH3),	1.25	(6H,	d,	J	=	6.9	Hz,	CH(CH3)2),	2.92	(1H,	sept,	J=	6.9	Hz,	
CH(CH3)2),	2.58	(2H,	q,	CH2),	3.29	(1H,	dd,	J	=	18.4,	4.8	Hz,	HA),	
3.81	(1H,	dd,	J	=	18.4,	11.9	Hz,	HB),	5.51	(1H,	dd,	J	=	11.9,	4.8,	1.0	
Hz,	HX),	 7.44‐7.27	 (4H,	m,	H	Ar),	 7.18‐7.14	 (4H,	m,	H	Ar).	 13C	
NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 15.13,	 23.91,	 23.93,	 33.79,	
40.56,	 41.95,	 58.79,	 125.61,	 126.65,	 127.05,	 128.81,	 130.62,	
130.97,	 138.94,	 147.69,	 154.75,	 159.30.	 Anal.	 calcd.	 for	
C21H23ClN2O:	C,	71.07;	H,	6.53;	N,	7.89.	Found:	C,	71.04;	H,	6.49;	
N,	7.85%.	
1‐(5‐(4‐Methylphenyl)‐3‐(4‐bromophenyl)‐4,5‐dihydro‐1H‐
pyrazol‐1‐yl)propan‐1‐one	 (10):	 Color:	 Pal	 crystal.	 Yield:	 78%.	
M.p.:	145‐144	°C.	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	1.15	(3H,	t,	
CH3),	1.20	(3H,	s,	CH3),	2.55	(2H,	q,	CH2),	3.27	(1H,	dd,	J	=	17.7,	
4.8	Hz,	HA),	3.75	(1H,	dd,	J	=	17.7,	11.7	Hz,	HB),	5.50	(1H,	dd,	J	=	
11.7,	4.8,	1.0	Hz,	HX),	7.77‐7.57	(4H,	m,	H	Ar),	7.42‐7.35	(4H,	m,	
H	Ar).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	15.10,	23.86,	40.55,	
42.58,	 58.79,	 125.62,	 126.69,	 126.90,	 128.73,	 130.60,	 130.85,	
137.35,	148.32,	155.55,	160.30.	Anal.	calcd.	for	C19H19BrN2O:	C,	
61.46;	H,	5.15;	N,	7.54.	Found:	C,	61.42;	H,	5.10;	N	7.52%.	
	
2.3.	Antimicrobial	activity	
	
The	 synthesized	 compounds	 6‐10	were	 screened	 in	 vitro	
for	 antibacterial	 activity	 against	 Escherchia	 coli,	 Salmonella	
typhi,	 Staphylococcus	 aureus	 and	 Bacillus	 subtilis	 at	 the	
concentrations	200,	300,	400	and	500	µg/mL	and	for	antifungal	
activity	 against	Aspergillus	niger	 at	 100,	 200,	 300,	 400	µg/mL	
by	 cup‐plate	 agar	 diffusion	 method	 [45].	 The	 concentrations	
used	 in	 screening	were	 chosen	 after	 determining	 the	MICs	 of	
each	 compound.	 The	 solvent	 used	 was	 dimethylsulfoxide	
(DMSO)	 further	 diluted	 with	 water.	 Muller	 Hinton	 agar	 was	
used	 as	 the	 growth	 medium	 for	 the	 bacterial	 species	 and	
Sabouraud's	 agar	 was	 the	 growth	 medium	 for	 the	 fungal	
species.	 DMSO	 was	 used	 as	 a	 control	 for	 all	 the	 type	 of	
microorganisms.	 The	 control	 showed	 no	 activity	 against	 the	
strains	of	microorganisms	used.	The	results	presented	in	Table	
1	and	2	are	obtained	after	48	hours	of	 incubation	at	35	°C	for	
antibacterial	 test	and	at	28‐30	°C	 for	antifungal	 test.	They	are	
compared	 with	 standard	 drugs	 penicillin	 for	 antibacterial	
activity	 and	 Greseofulvin	 for	 antifungal	 activity	 by	measuring	
the	zone	of	inhibition	in	mm.	
	
3.	Results	and	discussion	
	
Compounds	1‐5	 were	 treated	 with	 commercial	 hydrazine	
hydrate	 in	propanoic	 acid	under	 reflux.	The	progress	of	 these	
reactions	could	be	easily	monitored	by	TLC	showing	a	complete	
transformation	of	 starting	materials	 to	 single	products,	which	
were	 easily	 isolated	 by	 cooling	 at	 <0	 °C	 and	 filtration	 of	 the	
precipitated	 solid.	 Highly	 pure	 products	were	 isolated	 in	 this	
manner	 and	 were	 crystallized	 from	 ethanol.	 They	 were	
identified	 by	 IR	 and	 high	 field	 NMR	 spectroscopy	 as	 1‐((5,3‐
diaryl)‐4,5‐dihydro‐1H‐pyrazol‐1‐yl)propan‐1‐one,	6‐10.		
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Table	1.	Antibacterial	screening	results	of	the	compounds	6‐10.	
Compound	 Escherchia	Coli	 Salmonella	typhi	 Staphylococcus	aureus	 Bacillus	subtilis	
6	 09	 11	 14 12	
7	 14	 18	 26 17	
8	 15	 20	 28	 19	
9	 11	 14	 23	 13	
10	 10	 11	 19	 25	
Penicillin	 18	 25	 40	 17	
DMSO	 ‐	 ‐	 ‐ ‐	
‐No	antibacterial	activity	
	
	
Table	2.	Antifungal	screening	results	of	the	compounds	6‐10.	
Compound	 Aspergillus	niger	 Aspergillus	flavus Pencillium	chrysogenum Fusirium	moneliforme
6	 ‐	 +	 + +	
7	 ‐	 ‐	 + +	
8	 ‐	 ‐	 ‐ ‐	
9	 +	 +	 ‐ +	
10	 ‐	 +	 + +	
Greseofulvin		 ‐	 ‐	 ‐ ‐	
Control		 +	 +	 +	 +	
‐	No	Growth:	Antifungal	activity;	+	Growth:	No	antifungal	activity.		
	
	
The	 IR	spectrum	of	 these	compounds	exhibited	bands	due	
to:	C=O	of	propanoyl	group	at	1680	cm‐1,	C=N	of	pyrazoline	ring	
at	 1650	 cm‐1,	 C=C	 at	 1590	 cm‐1	 and	 C‐N	 at	 1150	 cm‐1.	
Furthermore,	their	1H	NMR	spectra	in	CDCl3	displayed	the	ethyl	
signals	of	the	propanoyl	group	at	1.12‐1.18	ppm	(triplet	of	CH3	
)	 and	 at	 2.52‐2.58	 ppm	 (quadruplet	 of	 CH2	 )	 as	 well	 as	 the	
characteristic	 ABX	 three‐spin	 system	 of	 the	 neighboring	
methylene	 and	methyne	 protons	 of	 the	 pyrazoline	 ring:	 5.50‐
5.54	ppm	(dd,	HX),	3.85‐3.75	ppm	(dd,	HB)	and	3.27‐3.32	ppm	
(dd,	 HA).	 The	 13C	 NMR	 spectra	 of	 all	 the	 compounds	 6‐10	
corroborated	 the	 1H‐pyrazole	 structure	 with	 the	 signals	 of	
carbon	 atoms	 C‐3	 (154‐156	 ppm),	 C‐4	 (41‐43	 ppm)	 and	 C‐5	
(57‐59	ppm)	as	well	as	the	presence	of	N‐propanoyl	group.	
The	 investigation	 of	 antibacterial	 screening	 results	
indicates	that	compounds	7	and	8	show	promising	activity	and	
compounds	 6	 and	 10	 poor	 activity	 against	 Escherchia	 coli.	
Compounds	 7	 and	 8	 show	 good	 activity	 against	 Salmonella	
typhi.	Compounds	7,	8	and	9	show	high	activity	and	compound	
6	shows	low	activity	against	Staphylococcus	areus.	Compounds	
6,	7,	8,	10	 show	 inhibitory	 effect	 against	 spergillus	 niger	 and	
compounds	7	 and	8	 show	 inhibitory	 effects	 against	 spergillus	
flavus.	 Compounds	 8,	 9	 show	 inhibitory	 effects	 against	
Penicillium	chrysogenum,	similar	compound	8	shows	inhibitory	
effect	against	Fusirium	moneliforme.	Remaining	compounds	are	
inactive	against	all	the	fingers.	
	
4.	Conclusion	
	
In	 conclusion,	 the	 synthesized	 1H‐pyrazoles	 having	
pharmacophores	 such	as	 chloro,	bromo	groups	are	present	 in	
one	 moiety	 exhibited	 best	 antimicrobial	 activity.	 The	 data	
reported	 in	this	article	may	be	helpful	guide	 for	 the	medicinal	
chemist	who	is	working	in	this	area.	
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